FY2023 · ended May 31, 2023 · Revenue $0, -100.0% YoY · Filed Aug 15, 2024
Cytodyn Inc. (CYDY) files with the SEC under industry code 2834, Pharmaceutical Preparations. As of Aug 31, 2026 it held $16.4 million in cash and investments and $35.9 million in total debt.
Revenue
$0
-100.0% vs prior year
Net income
$-42.70M
-1240.2% vs prior year
Operating cash flow (TTM)
$-22.53M
-35.3% vs year-ago TTM
Free cash flow
$-117.69M
-71.0% vs prior year
EPS
$-0.03
Dividend per share
None
Shares outstanding
1.38B
+10.4% vs prior year
Net cash
$-19.52M
as of Aug 31, 2026
Operating margin
-54663.2%
FY 2022
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CYDY (OTC)
- Fiscal year ends
- May 31
- Incorporated in
- DE
- Headquarters
- Vancouver, WA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1175680
- Former names
- CYTODYN INC (until Apr 13, 2016); REXRAY CORP (until Nov 12, 2003)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2026 May 31, 2026 |
FY 2025 May 31, 2025 |
FY 2024 May 31, 2024 |
FY 2023 May 31, 2023 |
FY 2022 May 31, 2022 |
|---|---|---|---|---|---|
| Revenue | — | — | — | $0 | $266,000 |
| Operating income | -$38.6M | $9.7M | -$18.1M | -$40.6M | -$145.4M |
| Net income | -$42.7M | $3.7M | -$49.8M | -$79.8M | -$210.8M |
| Diluted EPS | -$0.03 | $0.00 | -$0.05 | -$0.10 | -$0.31 |
| Operating cash flow | -$17.3M | -$8.8M | -$11.0M | -$25.1M | -$77.7M |
| Total assets | $14.0M | $18.0M | $11.1M | $11.3M | $29.2M |
| Total liabilities | $123.7M | $114.1M | $127.9M | $120.8M | $123.6M |
| Stockholders' equity | -$109.7M | -$96.0M | -$116.8M | -$109.5M | -$94.4M |
| Cash and investments | $11.9M | $11.9M | $3.1M | $2.5M | $4.2M |
| Total debt | $38.4M | $45.5M | $45.3M | $46.2M | $42.8M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Oct 19, 2026 | Oct 16, 2026 |
| 10-Q | Quarterly report | Oct 14, 2026 | Aug 31, 2026 |
| 10-K | Annual report | Aug 31, 2026 | May 31, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Apr 30, 2026 | Apr 30, 2026 |
| 10-Q | Quarterly report | Apr 8, 2026 | Feb 28, 2026 |
| 8-K |
Current report
Material agreement
|
Mar 24, 2026 | Mar 24, 2026 |
All 1001 Cytodyn Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.